MX2022015772A - Proteínas enpp1 o enpp3 solubles y sus usos. - Google Patents

Proteínas enpp1 o enpp3 solubles y sus usos.

Info

Publication number
MX2022015772A
MX2022015772A MX2022015772A MX2022015772A MX2022015772A MX 2022015772 A MX2022015772 A MX 2022015772A MX 2022015772 A MX2022015772 A MX 2022015772A MX 2022015772 A MX2022015772 A MX 2022015772A MX 2022015772 A MX2022015772 A MX 2022015772A
Authority
MX
Mexico
Prior art keywords
enpp3
enpp1
proteins
deficiency
compositions
Prior art date
Application number
MX2022015772A
Other languages
English (en)
Inventor
Zhiliang Cheng
Demetrios Braddock
Steven Jungles
Paul Stabach
Original Assignee
Inozyme Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inozyme Pharma Inc filed Critical Inozyme Pharma Inc
Publication of MX2022015772A publication Critical patent/MX2022015772A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04001—Phosphodiesterase I (3.1.4.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/01—Hydrolases acting on acid anhydrides (3.6) in phosphorus-containing anhydrides (3.6.1)
    • C12Y306/01009—Nucleotide diphosphatase (3.6.1.9), i.e. nucleotide-pyrophosphatase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

En determinados aspectos, la presente invención proporciona polipéptidos ENPP1 o ENPP3 solubles novedosos, así como composiciones y métodos para usar esas variantes para tratar una indicación 5 asociada a una deficiencia de ENPP1 o ENPP3. Las composiciones y métodos proporcionados en la presente descripción son útiles para tratar enfermedades asociadas con una deficiencia de ENPP1 o ENPP3 tales como calcificación patológica u osificación patológica.
MX2022015772A 2020-06-09 2021-06-08 Proteínas enpp1 o enpp3 solubles y sus usos. MX2022015772A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063036833P 2020-06-09 2020-06-09
PCT/US2021/036494 WO2021252549A1 (en) 2020-06-09 2021-06-08 Soluble enpp1 or enpp3 proteins and uses thereof

Publications (1)

Publication Number Publication Date
MX2022015772A true MX2022015772A (es) 2023-05-19

Family

ID=76731053

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015772A MX2022015772A (es) 2020-06-09 2021-06-08 Proteínas enpp1 o enpp3 solubles y sus usos.

Country Status (14)

Country Link
US (1) US20230313158A1 (es)
EP (1) EP4162036A1 (es)
JP (1) JP2023529892A (es)
KR (1) KR20230042263A (es)
CN (1) CN116157145A (es)
AR (1) AR122578A1 (es)
AU (1) AU2021286502A1 (es)
BR (1) BR112022024958A2 (es)
CA (1) CA3181983A1 (es)
CO (1) CO2023000016A2 (es)
IL (1) IL298853A (es)
MX (1) MX2022015772A (es)
TW (1) TW202214849A (es)
WO (1) WO2021252549A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023191898A1 (en) * 2022-03-30 2023-10-05 Yale University Method and compositions for treatment, amelioration, and/or prevention of diffuse idiopathic skeletal hyperostosis (dish)

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
GB8918616D0 (en) 1989-08-15 1989-09-27 Univ Glasgow Herpes simplex virus type 1 mutant
US20020164782A1 (en) 1999-02-10 2002-11-07 Gregory Richard J. Adenovirus vectors for gene therapy
AU668386B2 (en) 1992-03-25 1996-05-02 Depomed Systems, Incorporated Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
US5804413A (en) 1992-07-31 1998-09-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains for gene transfer
GB9415319D0 (en) 1994-07-29 1994-09-21 Medical Res Council HSV viral vector
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
WO1997047285A1 (en) 1996-06-10 1997-12-18 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
PT998271E (pt) 1997-06-06 2005-10-31 Depomed Inc Formas de dosagem oral de farmacos com retencao gastrica para a libertacao controlada de farmacos altamente soluveis
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
AU8605598A (en) 1997-07-31 1999-02-22 University Of Pittsburgh Targeted hsv vectors
IL149421A0 (en) 1999-11-02 2002-11-10 Depomed Inc Pharmaceutical compositions containing fed mode inducing agents
AU767812B2 (en) 2000-02-04 2003-11-27 Depomed, Inc. Shell-and-core dosage form approaching zero-order drug release
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US6451808B1 (en) 2000-10-17 2002-09-17 Depomed, Inc. Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
KR20040020056A (ko) 2001-05-29 2004-03-06 디포메드 디벨롭먼트 리미티드 위식도 역류 질환 및 야간 위산분비의 치료 방법
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
EP1438027A1 (en) 2001-10-25 2004-07-21 DepoMed, Inc. Methods of treatment using a gastric retained losartan dosage
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
US20070207124A1 (en) 2004-10-28 2007-09-06 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
PL2097533T3 (pl) 2006-11-28 2011-02-28 Proyecto De Biomedicina Cima Wektor wirusowy oraz jego zastosowania
ES2628841T3 (es) 2010-03-12 2017-08-04 Alexion Pharmaceuticals, Inc. Proteínas de fusión npp1
AU2011362576B2 (en) 2011-03-11 2017-06-08 Alexion Pharmaceuticals, Inc. NPP1 fusion proteins
JP6894664B2 (ja) 2013-02-13 2021-06-30 イエール ユニバーシティ 病的な石灰化および骨化を治療するための組成物および方法
ES2523016B1 (es) 2013-05-20 2015-09-09 3P Biopharmaceuticals Vectores alfavirales y líneas celulares para la producción de proteínas recombinantes
GB2526339A (en) 2014-05-21 2015-11-25 Imp Innovations Ltd Lentiviral vectors
CA2960912A1 (en) 2014-09-16 2016-03-24 Universitat Autonoma De Barcelona Adeno-associated viral vectors for the gene therapy of metabolic diseases
EP3967755B1 (en) * 2014-12-19 2024-03-27 Inozyme Pharma, Inc. Soluble npp1 for use in a method for treating pseudoxanthoma elasticum
JP6995627B2 (ja) 2015-05-19 2022-02-04 イエール ユニバーシティ 病的石灰化状態を治療するための組成物およびそれを使用する方法
EP3827835A1 (en) * 2016-06-16 2021-06-02 Inozyme Pharma, Inc. Methods of treating myointimal proliferation
EP3493829B1 (en) 2016-08-05 2024-04-17 Yale University Compositions and methods for stroke prevention in pediatric sickle cell anemia patients
JP2020535161A (ja) * 2017-09-27 2020-12-03 アレクシオン ファーマシューティカルズ， インコーポレイテッド 組換えエクトヌクレオチドピロホスファターゼ／ホスホジエステラーゼ（ｎｐｐ１）を使用して心血管機能を改善し、心血管疾患を処置するための方法。
CA3099266A1 (en) * 2018-05-08 2019-11-14 Yale University Compositions and methods for reducing progression of nephrolithiasis
US20220119782A1 (en) 2018-08-31 2022-04-21 Yale University ENPP1 Polypeptides and Methods of Using Same
JP2022527557A (ja) 2019-04-05 2022-06-02 イエール ユニバーシティ Ｅｎｐｐ１ポリペプチドおよびその使用方法

Also Published As

Publication number Publication date
BR112022024958A2 (pt) 2022-12-27
CO2023000016A2 (es) 2023-02-16
JP2023529892A (ja) 2023-07-12
IL298853A (en) 2023-02-01
AU2021286502A1 (en) 2023-01-19
KR20230042263A (ko) 2023-03-28
AR122578A1 (es) 2022-09-21
WO2021252549A1 (en) 2021-12-16
CN116157145A (zh) 2023-05-23
TW202214849A (zh) 2022-04-16
EP4162036A1 (en) 2023-04-12
US20230313158A1 (en) 2023-10-05
CA3181983A1 (en) 2021-12-16

Similar Documents

Publication Publication Date Title
MA44322A (fr) Compositions comprenant des souches bactériennes
CY1109985T1 (el) Αναστολεις πρωτεασωματος και μεθοδοι χρησης αυτων
MA42471A (fr) Compositions comprenant des souches bactériennes
MX2009009200A (es) Tratamiento de enfermedades caracterizadas por la inflamacion.
EA201900561A1 (ru) Конъюгаты циклодекстрин-белок-лекарственное средство
EA201990619A1 (ru) Fgf21 мутанты и их применение
MX2010008206A (es) Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf.
TW200730624A (en) Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
TW200745162A (en) Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
MXPA06014510A (es) Composiciones y metodos para tratar trastornos inflamatorios.
MY149606A (en) Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment
EA201892225A1 (ru) АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ
MY193350A (en) Anti-vegf protein compositions and methods for producing the same
MX2022002682A (es) Anticuerpos anti-cd73.
MX2019003077A (es) Anticuerpos novedosos contra el factor xi y sus usos.
MX2021009863A (es) Una molecula dbait en combinacion con inhibidor de quinasa para el tratamiento del cancer.
MX2022009762A (es) Moduladores del purinorreceptor 3 p2x (p2x3).
MX2022015772A (es) Proteínas enpp1 o enpp3 solubles y sus usos.
MX2021008503A (es) Tratamiento de enfermedades que involucran deficiencia de enpp1 o enpp3.
MX2021008834A (es) Metodos de tratamiento del cancer de mama con tucatinib.
MX2022014733A (es) Composiciones y métodos para inhibir la proliferación de células musculares lisas vasculares.
WO2019075216A8 (en) Plectin-1 binding antibodies and uses thereof
WO2020176461A3 (en) Methods and compositions for treating neuroendocrine prostate cancer
ATE445408T1 (de) Verwendung von prolactin in der prophylaktischen krebstherapie
MX2022002853A (es) Composiciones de neurotoxina para uso en el tratamiento de la gastroparesia.